Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. It also offers small and large animal models. In addition, the company provides cell-based assays, immunoassay, toxicology and cytotoxicity testing, viral load testing, and tailored assay development services; and Biocontainment, imaging services, and animal model development; and IND-enabling services, such as toxicology studies, pharmacokinetic profiling, GLP services, and regulatory documentation services. Bioqual, Inc. was incorporated in 1981 and is based in Rockville, Maryland.
Metrics to compare | BIOQ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIOQPeersSector | |
---|---|---|---|---|
P/E Ratio | −34.1x | −18.4x | −0.7x | |
PEG Ratio | 0.11 | −0.28 | 0.00 | |
Price/Book | 1.0x | 1.4x | 2.6x | |
Price / LTM Sales | 0.7x | 2.6x | 3.4x | |
Upside (Analyst Target) | - | 64.3% | 39.1% | |
Fair Value Upside | Unlock | 11.0% | 5.3% | Unlock |